Free Trial
NASDAQ:MDRX

Veradigm (MDRX) Stock Price, News & Analysis

Veradigm logo
$4.15 +0.15 (+3.75%)
As of 04/9/2025 03:58 PM Eastern

About Veradigm Stock (NASDAQ:MDRX)

Key Stats

Today's Range
$3.91
$4.23
50-Day Range
$3.90
$5.50
52-Week Range
$3.80
$11.80
Volume
651,856 shs
Average Volume
464,990 shs
Market Capitalization
$449.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Moderate Buy

Company Overview

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Remove Ads

Veradigm Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

MDRX MarketRank™: 

Veradigm scored higher than 40% of companies evaluated by MarketBeat, and ranked 223rd out of 309 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Veradigm has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Veradigm has only been the subject of 1 research reports in the past 90 days.

  • Read more about Veradigm's stock forecast and price target.
    • Short Interest

      There is no current short interest data available for MDRX.
    • Dividend Yield

      Veradigm does not currently pay a dividend.

    • Dividend Growth

      Veradigm does not have a long track record of dividend growth.

    • Short Interest

      There is no current short interest data available for MDRX.
    • News Coverage This Week

      MarketBeat has tracked 2 news articles for Veradigm this week, compared to 2 articles on an average week.
    Receive MDRX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Veradigm and its competitors with MarketBeat's FREE daily newsletter.

    MDRX Stock News Headlines

    Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
    Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
    Veradigm price target lowered to $5 from $9 at Deutsche Bank
    Veradigm updates shareholder rights agreement
    Veradigm Inc. (MDRX) Investor Update Call Transcript
    See More Headlines

    MDRX Stock Analysis - Frequently Asked Questions

    Veradigm's stock was trading at $9.75 at the beginning of the year. Since then, MDRX shares have decreased by 57.4% and is now trading at $4.15.
    View the best growth stocks for 2025 here
    .

    Veradigm Inc. (NASDAQ:MDRX) issued its earnings results on Thursday, November, 4th. The software maker reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.09. The firm's quarterly revenue was down 8.2% on a year-over-year basis.

    Veradigm subsidiaries include ZappRx, HealthGrid, and Practice Fusion.

    Shares of MDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Veradigm investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), General Electric (GE) and ServiceNow (NOW).

    Company Calendar

    Last Earnings
    11/04/2021
    Today
    4/10/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Industry
    Computer integrated systems design
    Sub-Industry
    Health Care Technology
    Current Symbol
    NASDAQ:MDRX
    Employees
    8,000
    Year Founded
    1986

    Price Target and Rating

    Average Stock Price Target
    $14.00
    High Stock Price Target
    $15.00
    Low Stock Price Target
    $13.00
    Potential Upside/Downside
    +237.3%
    Consensus Rating
    Moderate Buy
    Rating Score (0-4)
    2.50
    Research Coverage
    2 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $1.53 billion
    Price / Cash Flow
    N/A
    Price / Book
    N/A

    Miscellaneous

    Free Float
    105,175,000
    Market Cap
    $449.30 million
    Optionable
    No Data
    Beta
    0.63

    Social Links

    Reduce the Risk Cover

    Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

    Get This Free Report

    This page (NASDAQ:MDRX) was last updated on 4/10/2025 by MarketBeat.com Staff
    From Our Partners